Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer
Junyi Ju, … , Shi Jiao, Zhaocai Zhou
Junyi Ju, … , Shi Jiao, Zhaocai Zhou
Published March 21, 2024
Citation Information: J Clin Invest. 2024;134(10):e174587. https://doi.org/10.1172/JCI174587.
View: Text | PDF
Research Article Metabolism

The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer

  • Text
  • PDF
Abstract

Lactylation has been recently identified as a new type of posttranslational modification occurring widely on lysine residues of both histone and nonhistone proteins. The acetyltransferase p300 is thought to mediate protein lactylation, yet the cellular concentration of the proposed lactyl-donor, lactyl-coenzyme A, is about 1,000 times lower than that of acetyl-CoA, raising the question of whether p300 is a genuine lactyltransferase. Here, we report that alanyl-tRNA synthetase 1 (AARS1) moonlights as a bona fide lactyltransferase that directly uses lactate and ATP to catalyze protein lactylation. Among the candidate substrates, we focused on the Hippo pathway, which has a well-established role in tumorigenesis. Specifically, AARS1 was found to sense intracellular lactate and translocate into the nucleus to lactylate and activate the YAP-TEAD complex; and AARS1 itself was identified as a Hippo target gene that forms a positive-feedback loop with YAP-TEAD to promote gastric cancer (GC) cell proliferation. Consistently, the expression of AARS1 was found to be upregulated in GC, and elevated AARS1 expression was found to be associated with poor prognosis for patients with GC. Collectively, this work found AARS1 with lactyltransferase activity in vitro and in vivo and revealed how the metabolite lactate is translated into a signal of cell proliferation.

Authors

Junyi Ju, Hui Zhang, Moubin Lin, Zifeng Yan, Liwei An, Zhifa Cao, Dandan Geng, Jingwu Yue, Yang Tang, Luyang Tian, Fan Chen, Yi Han, Wenjia Wang, Shimin Zhao, Shi Jiao, Zhaocai Zhou

×

Figure 3

Lactylation promotes nuclear localization and stabilization of YAP-TEAD.

Options: View larger image (or click on image) Download as PowerPoint
Lactylation promotes nuclear localization and stabilization of YAP-TEAD....
(A) Left: Immunofluorescence analysis using anti-FLAG antibody showing nuclear translocation of YAP in HEK293A cells transfected with FLAG-tagged YAP or its K90R mutant following lactate treatment. Right: The signal intensity of FLAG-YAP was quantified using ImageJ software (NIH) (n = 3). N, nuclear localization; C, cytosolic localization; Lac, lactate. Data are presented as mean ± SD. Scale bar: 5 μm. (B) Nucleocytoplasmic distribution of heterologously expressed YAP or its K90R mutant in lactate-treated cells. Nuc, nuclear localization; Cyto, cytosolic localization. (C) Coimmunoprecipitation analysis showing the interaction of YAP or its K90R mutant with TEAD1 in lactate-treated cells. (D) Real-time quantitative PCR (qPCR) showing the mRNA levels of CTGF and CYR61 in HEK293A cells overexpressing YAP or its K90R mutant following lactate treatment (n = 3). Data are presented as mean ± SD. Glc, glucose. (E) ChIP-qPCR analysis for the enrichment of TEAD1 or its K108R mutant on the indicated genes’ promoter in lactate-treated HEK293FT cells (n = 3). Data are presented as mean ± SD. (F) KEGG analysis of the differentially expressed genes in the glucose-deprived HGC27 cells with or without 25 mM lactate. (G) Gene set enrichment analysis of the Hippo pathway signature in the glucose-deprived HGC27 cells with or without 25 mM lactate. (H) Nucleocytoplasmic distribution of lactylation and phosphorylation of YAP in YAP-overexpressing HEK293FT cells. (I) Lactylation of exogenous YAP and TEAD1 in lactate-treated HEK293A cells transfected with AARS1 or its NLS-deletion (ΔNLS) mutant. Unpaired 2-tailed Student’s t test (A, D, and E).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts